Abstract. The 
Prl levels in control rats, but failed to do so in rats bearing either macro-or (Annunziato 1980) and release (Perkins & Westfall 1978; Foreman & Porter 1981 (Casanueva et al. 1982 ). (Brawer et al. 1978 (Brawer et al. , 1983 Casanueva et al. 1982) (Fig. la,b) . (Fig. 3) .
FK 33-824 induced Prl responses similar to those evoked by DOM. It significantly increased Prl re¬ lease in control rats (P < 0.01 vs AUC of controls + saline) and in rats bearing microprolactinomas (P < 0.01 vs saline-treated rats), but not in rats bearing macroprolactinomas (P = NS vs respective controls) (Fig. 4) .
Discussion
It is known that repeated administration of huge doses of EV at 3-week intervals is associated to the development of prolactinomas in the pituitary gland of female rats (Brawer et al. 1978; Casanueva et al. 1982) . Our study shows that 7 months after EV withdrawal EV-induced tumoural changes are still present, yet size and morphologic appearance of the pituitary and plasma Prl levels allow to distinguish between micro-and macroprolactinomas.
In all rats, irrespective of whether bearing microor macroprolactinomas, acute injection of NOM, an indirect-acting DA agonist which releases DA and blocks DA re-uptake into the neuron terminals (Nicholson & Turner 1977) , proved to be ineffec¬ tive in lowering Prl release. NOM was instead effective in control rats. Although other interpretations may be possible (see below), the inability of NOM to lower plasma Prl in these rats very likely resides in a permanent defect in TIDA neuronal function following EV treatment. It appears unlikely that this failure might result from the inability of the lactotrophs to respond to the NOM-induced release of DA, since Prl responsiveness to the direct DA agonist bromo¬ criptine was increased in EV-treated rats develop¬ ing prolactinomas (Casanueva et al. 1982 (Gudelsky & Porter 1980) . The ability of opioid peptides to increase Prl secretion is believed to be mediated via inhibition of the TIDA system (Gudelsky & Porter 1979) , though the involvement of serotonin (5-HT) pathways has also been advo¬ cated (Koenig et 
